Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 11/20 | 0.61 |
| ▸ | PARP1 | P09874 | 5/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3734379 | 0.89 | DHODH (0.45) | DHODHPARP1GAACHEK2MGAM | |
| SCHEMBL275643 | 0.84 | HDAC6 (0.49) | DHODHPARP1HDAC6GAAMGAM | |
| SCHEMBL9289139 | 0.84 | DHODH (0.52) | DHODHPARP1HDAC6GAANPC1 | |
| SCHEMBL3734375 | 0.84 | RAB9A (0.56) | DHODHHDAC6GAANPC1RAB9A | |
| SCHEMBL6363407 | 0.84 | DHODH (0.56) | DHODHPARP1HDAC6GAANPC1 | |
| SCHEMBL6575742 | 0.81 | HDAC6 (0.63) | DHODHPARP1HDAC6GAANPC1 | |
| SCHEMBL1298432 | 0.78 | DHODH (0.94) | DHODHPARP1 | |
| SCHEMBL6574358 | 0.78 | L3MBTL1 (0.57) | DHODHPARP1GAA | |
| SCHEMBL989259 | 0.76 | L3MBTL1 (0.40) | DHODHPARP1 | |
| SCHEMBL39084 | 0.76 | HDAC6 (0.52) | DHODHPARP1HDAC6GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 959 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676428-A1 | LIQUID UV FILTER COMPOSITION CONTAINING DIOLS | Symrise AG (DE) | 2026-01-14 | — | — | EP | claimed |
| EP-4676433-A1 | LIQUID UV FILTER CONCENTRATE | Symrise AG (DE) | 2026-01-14 | — | — | EP | claimed |
| US-11723850-B2 | Liquid and transparent blend of UV filters | Symrise, AG (DE) | 2023-08-15 | — | — | US | claimed |
| US-11559557-B2 | Medicament comprising ginger root CO2 extract | SYMRISE AG (DE) | 2023-01-24 | — | — | US | claimed |
| US-20220354772-A1 | BLEND OF BEESWAX AND A LACTYLATE ESTER | SYMRISE AG (DE) | 2022-11-10 | — | — | US | claimed |
| EP-3993767-A1 | BLEND OF BEESWAX AND A LACTYLATE ESTER | Symrise AG (DE) | 2022-05-11 | — | — | EP | claimed |
| US-20220071872-A1 | A LIQUID AND TRANSPARENT BLEND OF UV FILTERS | SYMRISE AG (DE) | 2022-03-10 | — | — | US | claimed |
| EP-3873622-A1 | A LIQUID AND TRANSPARENT BLEND OF UV FILTERS | Symrise AG (DE) | 2021-09-08 | — | — | EP | claimed |
| CN-113164792-A | Liquid transparent mixtures of UV filters | 西姆莱斯股份公司 | 2021-07-23 | — | — | CN | claimed |
| WO-2021001029-A1 | BLEND OF BEESWAX AND A LACTYLATE ESTER | SYMRISE AG (DE) | 2021-01-07 | — | — | WO | claimed |
| US-6440401-B1 | 2-PHENYLBENZIMIDAZOLEDI- AND TRISULFONIC ACIDS; COSMETIC FORMULATIONS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-08-27 | — | — | US | claimed |
| WO-2002038537-A1 | NOVEL INDANYLIDENE COMPOUNDS | HAARMANN & REIMER GMBH (DE) | 2002-05-16 | — | — | WO | claimed |
| US-20020055532-A1 | UV-B filter | MERCK PATENT GESELLSCHAFT (DE) | 2002-05-09 | — | — | US | claimed |
| US-20020016349-A1 | UV-B filters | MERCK PATENT GESELLSCHAFT (DE) | 2002-02-07 | — | — | US | claimed |
| EP-1167358-A1 | 2-Phenylbenzimidazole sulphonic acids as UV-B filters | MERCK PATENT GmbH (DE) | 2002-01-02 | — | — | EP | claimed |
| WO-2001093822-A2 | AQUEOUS DISPERSIONS OF NANO-PARTICULATE UV-FILTERS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2001-12-13 | — | — | WO | claimed |
| US-6153174-A | Cosmetic compositions comprising a combination of UV absorbers | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-28 | — | — | US | claimed |
| US-6123929-A | A COSMETIC SUNSCREEN COMPRISES IN AN AQUEOUS PHASE A 2-PHENYLBENZIMIDAZOLE SULFONIC ACID OR SALT AND A FATTY PHASE CONTAINING A LINEAR OR CYCLIC MODIFIED POLYSILOXANE | ROCHE VITAMINS INC. (US) | 2000-09-26 | — | — | US | claimed |
| EP-0979645-A1 | Light screening composition containing a polysiloxane type UV-B screening agent and a benzimidazol type UV-B screening agent | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-16 | — | — | EP | claimed |
| EP-0838214-A2 | Cosmetic compositions containing a combination of UV-absorbers including a triazine derivative | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559557-B2 | Medicament comprising ginger root CO2 extract | CRY1, GRK1, GPER1 | DHODH 3047/4885PARP1 2136/4885HDAC6 2552/4885 |
| US-20020055532-A1 | UV-B filter | CBR1, UQCRB, H1-0 | DHODH 1470/4885PARP1 1843/4885HDAC6 2469/4885 |
| US-20220354772-A1 | BLEND OF BEESWAX AND A LACTYLATE ESTER | LAGE3, CRY1, BROX | DHODH 1354/4885PARP1 2451/4885HDAC6 3827/4885 |
| US-20020016349-A1 | UV-B filters | CBR1, H1-0, CYP1B1 | DHODH 1438/4885PARP1 1798/4885HDAC6 2506/4885 |
| US-11723850-B2 | Liquid and transparent blend of UV filters | F2, F12, F10 | DHODH 1774/4885PARP1 2961/4885HDAC6 2926/4885 |
| US-20220071872-A1 | A LIQUID AND TRANSPARENT BLEND OF UV FILTERS | F2, F12, TYR | DHODH 1710/4885PARP1 3064/4885HDAC6 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.